Trial reportEuropean journal of nutrition2021
Modulation of human intestinal microbiota in a clinical trial by consumption of a β-D-glucan-enriched extract obtained from Lentinula edodes.
Trial report in European journal of nutrition, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 41 citations in OpenAlex.
- Hypocholesterolemic agents and the gut microbiota: a review of interactions and modulatory activity.Pharmacological reports : PR · 2026Review
- A comprehensive review on structural, chemical, and functional perspectives of dietary polysaccharide-driven gut microbiota modulation: Mechanisms and challenges.Biochemistry and biophysics reports · 2026Review
- Medicinal Mushrooms and Their Bioactive Compounds: From Traditional Use to Therapeutic Potential.Molecules (Basel, Switzerland) · 2026Review
- Effects of regular consumption of a β-glucan-rich oyster mushroom powder on cholesterol metabolism in adults with moderately elevated LDL-cholesterol concentrations: a double-blind randomized controlled trial.Nutrition & metabolism · 2026Article
- Differential Safety and Lipid Control Efficacy of β-1,3/1,6-Glucan Oligosaccharides and Polysaccharides Derived FromFood science & nutrition · 2026Article
- Precision Delivery of Active Compounds from Edible and Medicinal Plants via Gut Microbiota Targeting: A New Paradigm for Cancer Immunotherapy.Nutrients · 2025Review
- Pleurotus Mushrooms in Nutrition and Health: Clinical and Preclinical Insights for Nutraceutical Development.Comprehensive reviews in food science and food safety · 2025Review
- Review
- Article
- Innovative applications of medicinal mushrooms in functional foods and nutraceuticals: a focus on health-boosting beverages.Frontiers in cellular and infection microbiology · 2025Review
- Selenopolysaccharide Isolated fromInternational journal of molecular sciences · 2024Article
- Therapeutic Potential of Fungal Polysaccharides in Gut Microbiota Regulation: Implications for Diabetes, Neurodegeneration, and Oncology.Journal of fungi (Basel, Switzerland) · 2024Review
- Screening Traditional Foods for the Prevention of EnterotoxigenicFoods (Basel, Switzerland) · 2024Article
- Medicinal Mushrooms as Multicomponent Mixtures-Demonstrated with the Example ofJournal of fungi (Basel, Switzerland) · 2024Review
- Modulation of gut microbiota by foods and herbs to prevent cardiovascular diseases.Journal of traditional and complementary medicine · 2023Review
- The Health and Clinical Benefits of Medicinal Fungi.Advances in biochemical engineering/biotechnology · 2023Article
- The benefits of edible mushroom polysaccharides for health and their influence on gut microbiota: a review.Frontiers in nutrition · 2023Review
- Gastrointestinal Effects and Tolerance of Nondigestible Carbohydrate Consumption.Advances in nutrition (Bethesda, Md.) · 2022Review
- The Effect of Novel Selenopolysaccharide Isolated fromBiomolecules · 2022Article
- Psilocybin containing mushrooms: a rapidly developing biotechnology industry in the psychiatry, biomedical and nutraceutical fields.3 Biotech · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeThe aim of this study was to evaluate the hypocholesterolemic, immune- and microbiota-modulatory effect of a mushroom extract in hypercholesterolemic subjects.
methodsA randomized, controlled, double-blind, and parallel clinical trial was carried out with subjects from 18 to 65 years old (n = 52) with untreated mild hypercholesterolemia. Volunteers consumed a β-D-glucan-enriched (BGE) mixture (10.4 g/day) obtained from shiitake mushrooms (Lentinula edodes) ensuring a 3.5 g/day of fungal β-D-glucans or a placebo incorporated in three different commercial creams.
resultsThis mixture showed hypocholesterolemic activities in vitro and in animal studies. After eight weeks intervention, no significant differences in lipid- or cholesterol-related parameters were found compared to placebo subjects as well as before and after the BGE mixture administration. No inflammatory or immunomodulatory responses were noticed and no changes in IL-1β, IL-6, TNF-α or oxLDL were recorded. However, consumption of the BGE mixture was safe and managed to achieve the dietary fibre intake recommended as cardiovascular protective diet. Moreover, the BGE mixture modulated the colonic microbiota differently compared to placebo. Microbial community composition varied from before to after the intervention with several genera being positively or negatively correlated with some biomarkers related to cholesterol metabolism.
conclusionThese results suggested a relation between cholesterol metabolism, microbiota and BGE administration. Nevertheless, the precise significance of this differential modulation was not fully elucidated and requires further studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.